Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Datasets
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients—sequentially, or better simultaneously?
Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)
Clinic of Radiotherapy
Arbeitsgruppe Angewandte Mathematik/Numerik
University of Kiel
Paracelsus Medical University
Friedrich Schiller University Jena
St. Marien-Krankenhaus Siegen
University of Düsseldorf
Vivantes Klinikum Neukolln
University of Erlangen–Nuremberg
formerly St.-Vincentius-Hospital Karlsruhe
St. Clara Hospital
Marien Hospital Stuttgart
University of Tubingen
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients—sequentially, or better simultaneously?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Nursing and Health Professions
Breast Cancer
100%
Neoadjuvant Therapy
100%
Capecitabine
100%
Trastuzumab Emtansine
100%
Medline
20%
Systemic Therapy
20%
Neoadjuvant Chemotherapy
20%
Drug Dose Reduction
20%
Medicine and Dentistry
Breast Cancer
100%
Neoadjuvant Therapy
100%
Capecitabine
100%
Trastuzumab Emtansine
100%
Systemic Therapy
20%
Drug Dose Reduction
20%
Neoadjuvant Chemotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Capecitabine
100%
Trastuzumab Emtansine
100%